Cymevir
Cymevir as Valganciclovir is an antiviral medication used to treat cytomegalovirus infections that may occur after an organ transplant (heart, kidney, or pancreas). Cymevir is a prodrug for ganciclovir. After oral administration, Cymevir rapidly convert into ganciclovir by intestinal and hepatic esterases. Also used to treat CMV retinitis in people who have acquired immunodeficiency syndrome (AIDS).
Composition:
Valganciclovir Tablets IP 450 mg
Mode of Action
Valganciclovir is a prodrug of ganciclovir, which is a synthetic analog of 2′-deoxy-guanosine. Its has same structure as ganciclovir, except for the addition of a L-valyl ester at the 5 end of the incomplete deoxyribose ring. The valine increases both the absorption of the drug in the intestines, as well as the bioavailability of the drug once it is absorbed. The L-valyl ester is cleaved by esterases in the intestines and the liver, leaving ganciclovir to be absorbed by the virus-infected cells. Ganciclovir is first phosphorylated to ganciclovir monophosphate by a viral thymidine kinase encoded by the cytomegalovirus (CMV) upon infection. Human cellular kinases further phosphorylate the molecule to create ganciclovir diphosphate, then ganciclovir triphosphate. These kinases are present in 10-fold greater concentrations in CMV or herpes simplex virus (HSV)-infected cells compared to uninfected human cells, allowing ganciclovir triphosphate to concentrate in infected cells. Ganciclovir triphosphate is a competitive inhibitor of deoxyguanosine triphosphate (dGTP). It is incorporated into viral DNA and preferentially inhibits viral DNA polymerases than cellular DNA polymerases more. Ganciclovir triphosphate serves as a poor substrate for chain elongation. Once incorporated into viral DNA due to its structure similarity to dGTP, chain termination occurs.
Indications
For Adult : Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. , • Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. | For Pediatric Patients : • Prevention of CMV disease in kidney and heart transplant patients at high risk.
Dosage
Prevention of CMV disease in heart or kidney-pancreas transplant patients -> Prevention of CMV disease in heart or kidney-pancreas transplant patients | Prevention of CMV disease in kidney transplant patients -> 900 mg (2 tablets) once a day within 10 days of transplantation until 200 days post-transplantation | Treatment of CMV retinitis -> 900 mg (two 450 mg tablets) twice a day for 21 days Maintenance: 900 mg (two 450 mg tablets) once a day | Prevention of CMV disease in kidney transplant patients 4 months to 16 years of age -> Dose once a day within 10 days of transplantation until 200 days post-transplantation | Prevention of CMV disease in kidney transplant patients 4 months to 16 years of age -> Dose once a day within 10 days of transplantation until 100 days post-transplantation
This information is for the registered medical practitioners only. Consult your medical practitioner before consuming the products.